Story

Replimune Shares Surge After FDA Grants Accelerated Approval for Melanoma Drug Tudriqev

ENTHMSVIIDZHZH-TWJAKOHI
Aug 7, 20262 min read
Replimune Shares Surge After FDA Grants Accelerated Approval for Melanoma Drug Tudriqev
Text size
Background

Shares of Replimune Group Inc. (REPL) surged in pre-market trading after the U.S. Food and Drug Administration (FDA) granted accelerated approval for its melanoma therapy, Tudriqev. The decision, announced late Thursday, clears the drug for use in combination with Bristol Myers Squibb’s nivolumab for adults with advanced, unresectable cutaneous melanoma that has progressed despite prior anti-PD-1 treatment.

FDA Reverses Stance on Trial Data

The approval marks a significant turnaround for Replimune, as the FDA had previously rejected the therapy on two separate occasions, citing insufficient evidence of effectiveness from the single-arm IGNYTE study. The agency has now granted accelerated approval based on data from that same Phase 1/2 trial.

Key findings from the IGNYTE study that supported the approval include:

  • An objective response rate (ORR) of 24.2% among 91 efficacy-evaluable patients.
  • A median duration of response (mDOR) of 14.1 months.

Because the approval was granted under the accelerated pathway, which relies on surrogate endpoints, Replimune will be required to verify the drug's clinical benefit in a confirmatory trial. The company's ongoing Phase 3 IGNYTE-3 study is expected to serve this purpose.

Sample IUX Markets – In-articleAd

Market Reaction and Analyst Outlook

Following the news, Replimune's stock reached a new 52-week high of $13.90 in pre-market activity. The FDA's decision was preceded by a series of positive analyst revisions. Leerink upgraded Replimune to Outperform and raised its price target to $17.00 from $11.00, with an analyst expressing "high conviction" in the approval and anticipating "strong demand."

Wedbush also upgraded the stock to Outperform from Neutral, setting a new price target of $12.00. Analysts see Tudriqev as a more accessible alternative to existing treatments like Iovance Biotherapeutics’ cell therapy Amtagvi, which involves a more complex treatment process and has a more challenging side-effect profile.

A Critical Lifeline for Replimune

The approval provides a crucial path forward for a therapy that the company had reportedly considered discontinuing if it faced another regulatory setback. The combination of the FDA green light and a supportive analyst community has provided a significant boost to the company's prospects in the competitive oncology market.

Read next

More on Stocks
Back to latest news

LATEST